Identification and analysis of anti-HDL scFv-antibodies obtained from phage display based synthetic antibody library. 2016

Priyanka Negi, and Janita Lövgren, and Päivi Malmi, and Nina Sirkka, and Jari Metso, and Tuomas Huovinen, and Eeva-Christine Brockmann, and Kim Pettersson, and Matti Jauhiainen, and Urpo Lamminmäki
Department of Biochemistry, Division of Biotechnology, University of Turku, Turku, Finland. Electronic address: priyanka.micro@gmail.com.

OBJECTIVE In epidemiological studies plasma high density lipoprotein cholesterol (HDL-C) levels are found to correlate inversely with atherosclerotic cardiovascular events. HDL consists of different subpopulations and they vary in their anti-atherogenic properties. The aim of this study is to isolate coronary artery disease (CAD) specific anti-HDL scFv-antibodies. METHODS To obtain CAD specific HDL binders, we used phage displayed synthetic antibody libraries to enrich specific antibodies against HDL isolated from CAD patients. The antibodies were affinity purified. Their capability to recognize apolipoproteins A-I and A-II, various HDL forms differing in lipid/protein ratios and plasma HDL, was studied using time-resolved fluorescence based immunoassay. RESULTS Using different selection strategies and immunoassay based screening we obtained altogether 1200 clones displaying HDL binding activity. By sequencing 337, we identified 264 unique antibodies against HDL. A set of 61 antibodies were selected for further analysis. We found a variety of antibodies with different binding profiles, including apoA-I binding antibodies either in lipid-dependent or lipid-independent manner and binders against apoA-II. Several antibodies were able to discriminate between HDL derived from CAD patients and healthy controls. A majority of the antibodies were immunoreactive with HDL in plasma. CONCLUSIONS The novel HDL recognizing antibodies isolated from synthetic antibody phage library have displayed interesting HDL-binding characteristics suggesting that, in addition to use as research tools, a part of them might be useful for the development of diagnostic methods for CAD risk assessment.

UI MeSH Term Description Entries
D008075 Lipoproteins, HDL A class of lipoproteins of small size (4-13 nm) and dense (greater than 1.063 g/ml) particles. HDL lipoproteins, synthesized in the liver without a lipid core, accumulate cholesterol esters from peripheral tissues and transport them to the liver for re-utilization or elimination from the body (the reverse cholesterol transport). Their major protein component is APOLIPOPROTEIN A-I. HDL also shuttle APOLIPOPROTEINS C and APOLIPOPROTEINS E to and from triglyceride-rich lipoproteins during their catabolism. HDL plasma level has been inversely correlated with the risk of cardiovascular diseases. High Density Lipoprotein,High-Density Lipoprotein,High-Density Lipoproteins,alpha-Lipoprotein,alpha-Lipoproteins,Heavy Lipoproteins,alpha-1 Lipoprotein,Density Lipoprotein, High,HDL Lipoproteins,High Density Lipoproteins,Lipoprotein, High Density,Lipoprotein, High-Density,Lipoproteins, Heavy,Lipoproteins, High-Density,alpha Lipoprotein,alpha Lipoproteins
D008297 Male Males
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D001435 Bacteriophages Viruses whose hosts are bacterial cells. Phages,Bacteriophage,Phage
D016022 Case-Control Studies Comparisons that start with the identification of persons with the disease or outcome of interest and a control (comparison, referent) group without the disease or outcome of interest. The relationship of an attribute is examined by comparing both groups with regard to the frequency or levels of outcome over time. Case-Base Studies,Case-Comparison Studies,Case-Referent Studies,Matched Case-Control Studies,Nested Case-Control Studies,Case Control Studies,Case-Compeer Studies,Case-Referrent Studies,Case Base Studies,Case Comparison Studies,Case Control Study,Case Referent Studies,Case Referrent Studies,Case-Comparison Study,Case-Control Studies, Matched,Case-Control Studies, Nested,Case-Control Study,Case-Control Study, Matched,Case-Control Study, Nested,Case-Referent Study,Case-Referrent Study,Matched Case Control Studies,Matched Case-Control Study,Nested Case Control Studies,Nested Case-Control Study,Studies, Case Control,Studies, Case-Base,Studies, Case-Comparison,Studies, Case-Compeer,Studies, Case-Control,Studies, Case-Referent,Studies, Case-Referrent,Studies, Matched Case-Control,Studies, Nested Case-Control,Study, Case Control,Study, Case-Comparison,Study, Case-Control,Study, Case-Referent,Study, Case-Referrent,Study, Matched Case-Control,Study, Nested Case-Control
D057127 Single-Chain Antibodies A form of antibodies consisting only of the variable regions of the heavy and light chains (FV FRAGMENTS), connected by a small linker peptide. They are less immunogenic than complete immunoglobulin and thus have potential therapeutic use. Fv Antibody Fragments, Single-Chain,ScFv Antibodies,Single-Chain Fv,Single-Chain Fv Antibody,Single-Chain Fv Antibody Fragments,Single-Chain Variable Fragment,Single-Chain Variable Fragment Antibodies,Single-Chain Variable Fragment Antibody,Single-Chain Variable Fragments,Antibodies, ScFv,Antibodies, Single-Chain,Antibody, Single-Chain Fv,Fragment, Single-Chain Variable,Fragments, Single-Chain Variable,Fv Antibody Fragments, Single Chain,Fv Antibody, Single-Chain,Fv, Single-Chain,Single Chain Antibodies,Single Chain Fv,Single Chain Fv Antibody,Single Chain Fv Antibody Fragments,Single Chain Variable Fragment,Single Chain Variable Fragment Antibodies,Single Chain Variable Fragment Antibody,Single Chain Variable Fragments,Variable Fragment, Single-Chain,Variable Fragments, Single-Chain

Related Publications

Priyanka Negi, and Janita Lövgren, and Päivi Malmi, and Nina Sirkka, and Jari Metso, and Tuomas Huovinen, and Eeva-Christine Brockmann, and Kim Pettersson, and Matti Jauhiainen, and Urpo Lamminmäki
December 2009, Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology,
Priyanka Negi, and Janita Lövgren, and Päivi Malmi, and Nina Sirkka, and Jari Metso, and Tuomas Huovinen, and Eeva-Christine Brockmann, and Kim Pettersson, and Matti Jauhiainen, and Urpo Lamminmäki
March 1996, The Journal of biological chemistry,
Priyanka Negi, and Janita Lövgren, and Päivi Malmi, and Nina Sirkka, and Jari Metso, and Tuomas Huovinen, and Eeva-Christine Brockmann, and Kim Pettersson, and Matti Jauhiainen, and Urpo Lamminmäki
November 2004, Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology,
Priyanka Negi, and Janita Lövgren, and Päivi Malmi, and Nina Sirkka, and Jari Metso, and Tuomas Huovinen, and Eeva-Christine Brockmann, and Kim Pettersson, and Matti Jauhiainen, and Urpo Lamminmäki
September 2016, Toxins,
Priyanka Negi, and Janita Lövgren, and Päivi Malmi, and Nina Sirkka, and Jari Metso, and Tuomas Huovinen, and Eeva-Christine Brockmann, and Kim Pettersson, and Matti Jauhiainen, and Urpo Lamminmäki
February 1997, Clinical and experimental immunology,
Priyanka Negi, and Janita Lövgren, and Päivi Malmi, and Nina Sirkka, and Jari Metso, and Tuomas Huovinen, and Eeva-Christine Brockmann, and Kim Pettersson, and Matti Jauhiainen, and Urpo Lamminmäki
January 2011, Cancer science,
Priyanka Negi, and Janita Lövgren, and Päivi Malmi, and Nina Sirkka, and Jari Metso, and Tuomas Huovinen, and Eeva-Christine Brockmann, and Kim Pettersson, and Matti Jauhiainen, and Urpo Lamminmäki
December 1995, Virology,
Priyanka Negi, and Janita Lövgren, and Päivi Malmi, and Nina Sirkka, and Jari Metso, and Tuomas Huovinen, and Eeva-Christine Brockmann, and Kim Pettersson, and Matti Jauhiainen, and Urpo Lamminmäki
June 1999, Journal of neuroimmunology,
Priyanka Negi, and Janita Lövgren, and Päivi Malmi, and Nina Sirkka, and Jari Metso, and Tuomas Huovinen, and Eeva-Christine Brockmann, and Kim Pettersson, and Matti Jauhiainen, and Urpo Lamminmäki
March 1998, Protein engineering,
Priyanka Negi, and Janita Lövgren, and Päivi Malmi, and Nina Sirkka, and Jari Metso, and Tuomas Huovinen, and Eeva-Christine Brockmann, and Kim Pettersson, and Matti Jauhiainen, and Urpo Lamminmäki
January 1997, Molecular immunology,
Copied contents to your clipboard!